Pediatric phase I drug tolerance: A review and comparison of recent adult and pediatric phase I trials

Journal of Pediatric Hematology/Oncology

Volumn 18, Issue 3, 1996, Pages 250-256

  Carlson, Lisa ^a   Ho, Peter ^b   Smith, Malcolm ^b   Reisch, Joan ^a   Weitman, Steven ^c,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Cancer chemotherapy; Maximum tolerated dose; Phase I trials

Indexed keywords

3 DEAZAURIDINE; 6 DIAZO 5 OXONORLEUCINE; ALANOSINE; ANCITABINE; ANTINEOPLASTIC AGENT; BISANTRENE; CARBOPLATIN; DIANHYDROGALACTITOL; DIAZIQUONE; DOCETAXEL; FAZARABINE; INDICINE N OXIDE; MELPHALAN; MITOFLAXONE; MITOXANTRONE; NITROSOUREA DERIVATIVE; PACLITAXEL; PIRITREXIM; RAZOXANE; SPIROMUSTINE; TIAZOFURIN; TOPOTECAN; TRIMETREXATE; ZORUBICIN;

ADULT; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS, PHASE I; DRUG TOLERANCE; HUMANS; NEOPLASMS; REGRESSION ANALYSIS;

EID: 0029934221     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199608000-00003     Document Type: Review

References (83)

1. Glaubiger DL, Von Hoff DD, Holcenberg JS, et al. The relative tolerance of children and adults to anticancer drugs. Front Radiat Ther Oncol 1982;16:42-9.
2. Marsoni S, Ungerleider RS, Hurson SB, et al. Tolerance to antineoplastic agents in children and adults. Cancer Treat Rep 1985;69:1263-9.
3. Microsoft Excel, version 5.0c. Redmond, WA: Microsoft Corporation.
4. Zar J. Simple linear regression. In: Biostatistical analysis, 2nd ed., Englewood Cliffs, N.J.: Prentice-Hall, 1984:261-76.
5. SAS/STAT user's guide, 4th ed. SAS Institute, Cary, NC, 1990:1385.
6. Finklestein JZ, Higgins G, Krivit W, et al. Evaluation of cyclocytidine in children with advanced acute leukemia and solid tumors. Cancer Treat Rep 1979;63:1331-3.
7. Lokich JJ, Chawla PL, Jaffe N, et al. Phase I evaluation of cyclocytidine (NSC-145668). Cancer Chemother Rep 1975;59:389-93.
8. Burgess MA, Bodey GP, Minow RA, et al. Phase I-II evaluation of cyclocytidine. Cancer Treat Rep 1977:61:437-43.
9. Higgins GR, Shore NA, Etcubanas E, et al. Dianhydrogalactitol: Phase I clinical pharmacological studies in childhood cancer. Proc Am Assoc Cancer Res 1976;165:658.
10. Eagan RT, Moertel CG, Hahn RG, et al. Phase I study of a five-day intermittent schedule for 1,2:5,6-dianhydrogalactitol (NSC-132313) [Brief Communication]. J Natl Cancer Inst 1976;56: 179-81.
11. Miser JS, Miser AW, Smithson WA, et al. A Phase I trial of indicine N-oxide in childhood malignancy. Proc Am Soc Clin Oncol 1982;1:137.
12. Kovach JS, Ames MM, Powis G, et al. Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans. Cancer Res 1979;39:4540-4.
13. Rivera G, Pratt CB. Phase I study of 3-deazauridine (NSC 126849) in children with cancer. Clin Pharmacol Ther 1979;25:244-5.
14. Creaven PJ, Priore RL, Mittelman A, et al. Phase I trial and pharmacokinetics of a daily 5 schedule of 3-deazauridine. Cancer Treat Rep 1982;66:81-4.
15. Pediatric Oncology Group, Operations Office, SWOG 7843.
16. Benjamin RS, Keating MJ, Swenerton KD, et al. Clinical studies with rubidazone. Cancer Treat Rep 1979;63:925-9.
17. Sullivan MP, Nelson JA, Feldman S, et al. Pharmacokinetic and Phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. Cancer Chemother Pharmacol 1988;21:78-84.
18. Sklaroff RB, Casper ES, Magill GB, et al. Phase I study of 6-diazo-5-oxo-L-norleucine (DON). Cancer Treat Rep 1980;64:1247-51.
19. Pediatric Oncology Group, Operations Office, POG 8155.
20. Dosik GM, Stewart D, Valdivieso M, et al. Phase I study of L-alanosine using a daily 3 schedule. Cancer Treat Rep 1982;66:73-6.
21. Holcenberg JS, Tutsch KD, Earhart RH, et al. Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rep 1986; 70:703-9.
22. Von Hoff DD, Howser D, Lewis BJ, et al. Phase I study of ICRF-187 using a daily for 3 days schedule. Cancer Treat Rep 1981; 65:249-52.
23. Tan CTC, Hancock CH, Mondora A, et al. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986). Cancer Res 1984; 44:831-5.
24. Ettinger LJ, Siegel SE, Belasco JB, et al. Phase I clinical evaluation of diaziquone in childhood cancer. Cancer Treat Rep 1985;69: 323-7.
25. Bedikian AY, Bodey GP, Burgess MA, et al. Phase I study of aziridinylbenzoquinone (NSC 182986). Cancer Clin Trials 1981; 4:459-63.
26. Griffin JP, Newman RA, McCormack JJ, et al. Clinical and clinical pharmacologic studies of aziridinylbenzoquinone. Cancer Treat Rep 1982;66:1321-5.
27. CTEP annual report, 1982.
28. Ohnuma T, Sridhar KS, Ratner LH, et al. Phase I study of indicine N-oxide in patients with advanced cancer. Cancer Treat Rep 1982;66:1509-15.
29. Taylor S, Belt R, Haas C, et al. Phase I studies of indicine N-oxide (IND) in two dose schedules. Proc Am Assoc Cancer Res 1980; 342:90.
30. Cook BA, Sinnhuber JR, Thomas PJ, et al. Hepatic failure secondary to indicine N-oxide toxicity: a Pediatric Oncology Group Study. Cancer 1983;52:61-3.
31. Bacha DM, Caparros-Sison B, Allen JA, et al. Phase I study of carboplatin (CBDCA) in children with cancer. Cancer Treat Rep 1986;70:865-9.
32. Priego V, Luc V, Bonnem E, et al. A Phase I study and pharmacology of diammine (1,1) cyclobutane dicarboxylato (2-1-0) platinum (CBDCA) administered on a weekly schedule. Proc Am Soc Clin Oncol 1983;2:117.
33. CTEP annual report, 1988.
34. Pratt CB, Sinkule JA, Etcubanas E, et al. Phase I clinical and pharmacokinetic study of bisantrene in refractory pediatric solid tumors. Invest New Drugs 1986;4:149-53.
35. Spiegel RJ, Blum RH, Levin M, et al. Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule. Cancer Res 1982;42:354-8.
36. Gaynon PS, Ettinger LJ, Moel D, et al. Pediatric Phase I trial of carboplatin: a Children's Cancer Study Group report. Cancer Treat Rep 1987;71:1039-42.
37. Leyvraz S, Ohnuma T, Lassus M, et al. Phase I study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion. J Clin Oncol 1985;3:1385-92.
38. Koeller JM, Trump DL, Tutsch KD, et al. Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion. Cancer 1986;57:222-5.
39. Joss RA, Kaplan S, Goldhirsch A, et al. A Phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. Invest New Drugs 1984;2:297-304.
40. Calvert AH, Harland SJ, Newell DR, et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982;9:140-7.
41. Balis FM, Lange BJ, Packer RJ, et al. Pediatric Phase I trial and pharmacokinetic study of tiazofurin (NSC 286193). Cancer Res 1985;45:5169-72.
42. Roberts JD, Stewart JA, McCormack JJ, et al. Trial of tiazofurin administered by IV bolus daily for 5 days, with pharmacokinetic evaluation. Cancer Treat Rep 1987;71:141-9.
43. Maroun JA, Stewart DJ. Phase I study of tiazofurin (2-B-D-ribofuranosylthiazole-4-carboxamide. NSC 286193). Invest New Drugs 1990;8:S33-9.
44. Melink TJ, Von Hoff DD, Kuhn JG, et al. Phase I evaluation and pharmacokinetics of tiazofurin (2-B-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Cancer Res 1985;45:2859-65.
45. Neidhart J, Metz E, Gochnour D, et al. Phase I study of tiazofurin (2-B-D-ribofuranosyl-4-thiazole-carboxamide; NSC 286193). Proc Am Soc Clin Oncol 1984;3:36.
46. Ungerleider RS, Pratt CB, Vietti TJ, et al. Phase I trial of mitoxantrone in children. Cancer Treat Rep 1985;69:403-7.
47. Von Hoff DD, Pollard E, Kuhn J, et al. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis2-[(2-hydroxyethyl)amino]ethyl:amino:: -9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. Cancer Res 1980;40:1516-8.
48. Von Hoff DD, Myers JW, Kuhn J, et al. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942). Cancer Res 1981;41:3118-21.
49. Balis FM, Patel R, Luks E, et al. Pediatric Phase I trial and pharmacokinetic study of trimetrexate. Cancer Res 1987;47:4973-6.
50. Fanucchi MP, Walsh TD, Fleisher M, et al. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res 1987;47:3303-8.
51. Huan SD, Legha SS, Raber MN, et al. Phase I studies of trimetrexate using single and weekly dose schedules. Invest New Drugs 1991;9:199-206.
52. Heideman RL, Kelley JA, Packer RJ, et al. A pediatric Phase I and pharmacokinetic study of spirohydantoin mustard. Cancer Res 1988;48:2292-5.
53. Brown TD, Ettinger DS, Donehower R. A Phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer. J Clin Oncol 1986;4:1270-6.
54. Heideman RL, Gillespie A, Ford H, et al. Phase I trial and pharmacokinetic evaluation of fazarabine in children. Cancer Res 1989;49:5213-6.
55. Bailey H, Tutsch KD, Arzoomanian RZ, et al. Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion. Cancer Res 1991;51:1105-8.
56. Pratt CB, Relling MV, Meyer WH, et al. Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors. Am J Clin Oncol 1991;14:483-6.
57. CTEP annual report, 1991.
58. Pappo AS, Vats T, Williams TE, et al. Phase I trial of trimetrexate in pediatric solid tumors: a Pediatric Oncology Group study. Med Pediatr Oncol 1993;21:280-2.
59. Stewart JA, McCormack JJ, Tong W, et al. Phase I clinical and pharmacokinetic study of trimetrexate using a daily ◇5 schedule. Cancer Res 1988;48:5029-35.
60. Grochow LB, Noe DA, Dole GB, et al. Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics. J Natl Cancer Inst 1989;81:124-30.
61. Adamson PC, Balis FM, Miser J, et al. Pediatric Phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule. Cancer Res 1990;50:4464-7.
62. Brenckman W, Laszlo J, Morgan E, et al. Phase I evaluation of BW 301U administered orally on five consecutive days. Proc Am Soc Clin Oncol 1985;4:45.
63. Laszlo J, Brenckman WD, Morgan E, et al. Initial clinical studies of piritrexim. Natl Cancer Inst Monogr 1987;5:121-5.
64. Blaney SM, Balis FM, Cole DE, et al. Pediatric Phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993;53:1032-6.
65. Reid JM, Burch PA, Benson LM, et al. Phase I clinical and pharmacologic evaluation of topotecan administered by a 24-hour continuous infusion. Proc Am Assoc Cancer Res 1992;33:1553.
66. Abbruzzese JL, Madden T, Schmidt S, et al. Phase I trial of topotecan (TT) administered by 24-hour infusion without and with g-CSF. Proc Am Assoc Cancer Res 1993;34:329.
67. ten Bokkel Huinink WW, Rodenhuis S, Beijnen J. et al. Phase I study of the topoisomerase I inhibitor topotecan (SK &F 104864-A). Proc Am Soc Clin Oncol 1992;11:110.
68. Recondo G, Abbruzzese J, Newman B, et al. A Phase I trial of topotecan (TOPO) administered by a 24-hour infusion. Proc Am Assoc Cancer Res 1991;32:206.
69. Hurwitz CA, Relling MV, Weitman SD, et al. Phase I trial of taxol in children with refractory solid tumors: a Pediatric Oncology Group Study. J Clin Oncol 1993;11:2324-9.
70. Wiernik PH, Schwartz EL, Einzig A, et al. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987;5:1232-9.
71. Horikoshi N, Ogawa M, Inoue K, et al. Pharmacokinetics of a 24 hour infusion of taxol. Proc Am Soc Clin Oncol 1993;12:146.
72. Tamura T, Sasaki Y, Shinkai T, et al. Phase I and pharmacokinetic study of taxol by a 24-hour intravenous infusion. Proc Am Soc Clin Oncol 1993;12:143.
73. Seibel N, Ames M, Ivy P, et al. Phase I and pharmacologic study of paclitaxel in refractory pediatric leukemia: a Children's Cancer Group study. Proc Am Soc Clin Oncol 1994;13:1068.
74. Weitman SD, Relling MV, Hurwitz CA. Taxol: the pediatric experience. In: McGuire W, Rowinsky E, eds. Taxol in cancer treatment. New York: Marcel Dekker, Inc., 1995:307-19.
75. Tubergen D, Pratt C, Stewart C, et al. Phase I study of topotecan in children with refractory solid tumors: a Pediatric Oncology Group study. Proc Am Soc Clin Oncol 1994;13:167.
76. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-56.
77. Saltz L, Sirott M, Young C, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony stimulating factor. J Natl Cancer Inst 1993;85:1499-507.
78. Verweij J, Lund B, Beijnen J, et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993;4:673-8.
79. Pratt CB, Stewart C, Santana VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994;12:539-43.
80. Burris HA, Awada A, Kuhn JG, et al. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 hour continuous infusion. Anti-Cancer Drugs 1994;5:394-402.
81. Blaney S, Seibel N, O'Brien M, et al. A Phase I study of taxotere in pediatric patients. Proc Am Assoc Cancer Res 1994;35:211.
82. Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993;53:1037-42.
83. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993;11:950-8.